Squarepoint’s Acrivon Therapeutics ACRV Stock Holding History

Squarepoint’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.7K	Sell	13,309 -14,163	-52%	-$24.1K	﹤0.01%	4305
2026 Q1	$38.2K	Buy	27,472 +1,310	+5%	+$2.29K	﹤0.01%	4157
2025 Q4	$63K	Sell	26,162 -78,162	-75%	-$170K	﹤0.01%	4107
2025 Q3	$189K	Sell	104,324 -48,281	-32%	-$67.9K	﹤0.01%	3965
2025 Q2	$182K	Buy	+152,605	New	+$209K	﹤0.01%	4010
2024 Q3	–	Sell	-17,207	Closed	-$99.8K	–	4051
2024 Q2	$99.8K	Buy	+17,207	New	+$139K	﹤0.01%	3801

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's ACRV Position: Q2 2026 in Review

Squarepoint reduced its Acrivon Therapeutics (ACRV) stake by 52% in Q2 2026, selling an estimated $24.1K and leaving 13,309 shares worth $23.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4305.

Squarepoint first reported a position in ACRV in Q2 2024 and has held it in 6 quarters since. The position peaked at $189K in Q3 2025. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

Squarepoint held 13,309 shares of Acrivon Therapeutics worth $23.7K as of Q2 2026.
Squarepoint sold 14,163 Acrivon Therapeutics shares in Q2 2026, an estimated $24.1K.
Acrivon Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4305 holding.
Squarepoint first reported a position in Acrivon Therapeutics in Q2 2024 and has held it in 6 quarters since.
Squarepoint's Acrivon Therapeutics position peaked at $189K in Q3 2025.
46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.